New Breast Cancer Trial Evaluates Chemotherapy Necessity
A clinical study is testing if some patients with high-risk breast cancer can safely skip chemotherapy.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Should medical treatments prioritize tumor biology testing to reduce unnecessary chemotherapy for breast cancer patients?
The ECOG-ACRIN Cancer Research Group has launched the RxFINE-Low (EA1242) clinical trial to determine if chemotherapy provides a meaningful benefit to certain breast cancer patients. This study targets postmenopausal individuals with specific tumor characteristics who may be candidates for treatment de-escalation.
Why it matters
The trial aims to determine if tumor biology can guide treatment decisions to spare patients from unnecessary treatment-related toxicities. These findings may refine how physicians manage care for patients who appear high-risk anatomically but have low-risk genomic profiles.
The RxFINE-Low trial is a randomized study enrolling nearly 2,000 participants to compare adjuvant chemotherapy plus endocrine therapy and ribociclib against endocrine therapy plus ribociclib alone. Researchers will follow participants for up to 10 years to measure survival and recurrence.
The players
ECOG-ACRIN Cancer Research Group
A multidisciplinary research organization that designs and conducts large-scale clinical trials to improve cancer treatment.
National Cancer Institute
The federal government's principal agency for cancer research and training.
Novartis Pharmaceuticals Corporation
A pharmaceutical company that produces ribociclib, a targeted therapy used in breast cancer treatment.
The details
Participants are being randomized 1:1 to either receive chemotherapy alongside endocrine therapy and the drug ribociclib or to forgo chemotherapy in favor of endocrine therapy and ribociclib alone. The trial focuses on patients with ER+/HER2- breast cancer who meet high anatomic risk criteria, defined as tumors larger than 5 cm or involvement of more than three lymph nodes, but maintain a low genomic risk, specifically an Oncotype DX Breast Recurrence Score between 0 and 25.
Timeline
September 24, 2026: Launch of the RxFINE-Low trial.
10 years: Follow-up period for study participants.
Health Landscape
This trial builds on the established use of the Oncotype DX Breast Recurrence Score as a prognostic tool to guide clinical decisions regarding chemotherapy usage. It expands the current evidence base by specifically evaluating if genomic markers can safely identify patients who may not require chemotherapy despite having high anatomic disease markers.
If you are a postmenopausal patient with an ER+/HER2- breast cancer diagnosis, talk to your doctor about whether your tumor's anatomic and genomic characteristics make you a candidate for current clinical trials. Because trial findings could influence future standards of care and insurance coverage for testing, stay informed about new evidence from the National Cancer Institute.
The takeaway
The RxFINE-Low trial represents a shift toward using precision biological data to determine if high-risk anatomic features can be managed without traditional chemotherapy. Patients interested in trial participation or treatment de-escalation should discuss the relevance of Oncotype DX testing with their oncologist.
Further reading
For more information on current treatment standards, visit the Cancer section.
More information
View the full details regarding RxFINE-Low trial eligibility and site information.
Source note: This article includes information reported by News-Medical.
Live Poll
Should medical treatments prioritize tumor biology testing to reduce unnecessary chemotherapy for breast cancer patients?
